Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood filter shows promise for liver failure patients

NCT ID NCT05129904

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a blood-filtering treatment called DPMAS for people with severe liver failure. The goal is to see if it can lower the risk of death or worsening disease within weeks. About 1300 adults with chronic liver disease and high bilirubin levels are taking part. Researchers will also collect blood, urine, and stool samples to better understand who benefits most.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Given the global heterogeneity of current regional diagnostic criteria for ACLF, the study enrolled a subgroup of patients with chronic liver disease (CLD) related ACLF defined by total bilirubin ≥ 12 mg/dL and INR level ≥ 1.5, which simultaneously fulfilled the diagnostic criteria recommended by Chinese and Asia-Pacific, while a considerable proportion also fulfilled the ACLF diagnostic criteria defined by European guidelines. This study population is characterized by markedly elevated bilirubin levels, making it well aligned with real-world clinical practice given that DPMAS intervention selectively targets bilirubin adsorption. Additionally, previous data have suggested that this specific patient population associated with a high rate of disease progression rate (approximately 40%) and high mortality (over 20%), further suggesting that the enrolled population is suitable for screening the optimal ACLF subgroup with favorable responses to DPMAS.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Hospitalized patients 2. Age \>18 years 3. Chronic liver disease regardless of the etiology 4. Total bilirubin ≥ 12mg/dl and INR ≥ 1.5 Exclusion Criteria: 1. With ≥ 3 organ failures (SOFA criteria); 2. The pregnant; 3. With severe non-hepatic disease (such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission); 4. Human immunodeficiency virus (HIV) infection without treatment; 5. Patients with unstable hemodynamics caused by infection or acute bleeding; 6. Hospital stays \<48 hours; 7. Diagnosis of hepatocellular carcinoma during screening period; 8. For the DPMAS clusters: patients decline to receive DPMAS treatment alone or in combination with PE; 9. For the SOC clusters: patients plan to receive DPMAS therapy; 10. Not suitable to participate in this study judging by researchers (e.g., patients with severe advanced pancreatic tumors, hematological tumors); 11. Not sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dpmas therapy in liver disease patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dpmas therapy in liver disease patients

Contacts and locations

Locations

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • Beijing Youan Hospital, Capital Medical University

    Beijing, China

  • Chengdu Public Health Clinical Center

    Chengdu, China

  • First Affiliated Hospital of Anhui Medical University

    Hefei, China

  • First Affiliated Hospital of Fujian Medical University

    Fujian, China

  • General Hospital of Ningxia Medical University

    Qinghai, China

  • Guizhou Provincial People's Hospital

    Guizhou, China

  • Hainan Provincial People's Hospital

    Hainan, China

  • Henan Provincial People's Hospital

    Henan, China

  • Huashan Hospital, Fudan University

    Shanghai, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • Infectious Diseases Hospital Affiliated to Nanchang University

    Nanchang, China

  • Luhe Hospital, Capital Medical University

    Beijing, China

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fujian, China

  • Nanfang Hospital

    Guangzhou, Guangdong, 510515, China

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

  • Peking University People's Hospital

    Beijing, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shandong Provincial Clinical Center for Public Health

    Jinan, Shandong, China

  • Shanghai Jiao Tong University Affiliated Sixth People's Hospital

    Shanghai, China

  • Shanghai Public Health Clinical Centre

    Shanghai, China

  • Shanghai Public Health Clinical Centre, Fudan University

    Shanghai, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Southwest Hospital, Third Military Medical University

    Chongqing, China

  • Taihe Hospital, Hubei University of Medicine

    Hubei, China

  • The Affiliated Hospital of Guizhou Medical University

    Guizhou, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • The Affiliated Hospital of Zunyi Medical University

    Guizhou, China

  • The First Affiliated Hospital of Guangxi Medical University

    Guangxi, China

  • The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine

    Guangxi, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong, China

  • The First Affiliated Hospital of Shanxi Medical University

    Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Xinjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Zhejiang, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Hospital of Lanzhou University

    Lanzhou, China

  • The First Hospital of Yunnan Province

    Kunming, Yunnan, China

  • The First People's Hospital of Foshan

    Foshan, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Guangxi, China

  • The Second Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Guangxi Medical University

    Guangxi, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, China

  • The Second Hospital of Hebei Medical University

    Hebei, China

  • The Second Hospital of Shandong University

    Jinan, Shandong, China

  • The Second Xiangya Hospital, Central South University

    Changsha, China

  • The Third Hospital of Hebei Medical University

    Hebei, Hebei, China

  • Tianjin Third Central Hospital

    Tianjin, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Hubei, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhengzhou University Affiliated Luoyang Centre Hospital

    Luoyang, China